CompletedPhase 3NCT01087801

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

Studying Genetic pancreatic disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
ChiRhoClin, Inc.
Principal Investigator
Frank Burton, M.D.
St. Louis University
Intervention
ChiRhoStim(drug)
Enrollment
64 target
Eligibility
18 years · All sexes
Timeline
2007 – 2009

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01087801 on ClinicalTrials.gov

Other trials for Genetic pancreatic disease

Additional recruiting or active studies for the same condition.

See all trials for Genetic pancreatic disease →

← Back to all trials